CERo Therapeutics is a clinical-stage biotech developing engineered T cell therapies for cancer. CERo has no approved products and generates no revenue. Its entire pipeline centers on a single lead asset, CER-1236, an autologous T cell therapy currently in Phase 1 trials. CER-1236 uses a novel mechanism that combines conventional T cell cytotoxic killing with phagocytic clearance — physically engulfing cancer cells — normally associated with the innate immune system. The therapy targets TIM-4 ligand (phosphatidylserine), a molecule broadly expressed on cancer cell surfaces but largely absent from healthy tissue, which CERo argues could allow CER-1236 to work across a wide range of tumor types. The initial focus is acute myeloid leukemia, a blood cancer with no currently approved CAR-T therapy. The Phase 1 trial began in May 2025 and has been expanded to include myelodysplastic syndrome and myelofibrosis. CERo has also received FDA clearance for a second trial targeting non-small cell lung cancer and ovarian cancer, anticipated to begin in the second half of 2026. CERo's strategy is to progressively expand CER-1236's indications, leveraging its broad tumor target. The company has eight full-time employees and outsources manufacturing to contract manufacturers. CERo holds FDA Orphan Drug and Fast Track designations for AML, and is entirely funded by capital raises to support ongoing R&D and clinical development.